1.465USD-2.98%Mkt Cap: 101.33M USDP/E: —Last update: 2026-06-01
PepGen Inc., a clinical-stage biotechnology company, develops oligonucleotide therapeutics for the treatment of severe neuromuscular and neurologic diseases in the United States. The company engages in the development of…
Industry Peers
Biotechnology111.39BUSDP/E 26.0
100.62BDKKP/E 19.4
62.97BUSDP/E 14.7
48.39BEURP/E 31.7
44.65BEURP/E 37.2
40.10BUSDP/E 75.3
35.22BUSD—
32.91BSEKP/E 48.6
Indicators:|
Key Statistics
Company
Market Cap101.33M USD
Enterprise Value-11.99M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-89.66M USD
Revenue/Share—
Last Price1.465 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees56
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-1.17
PEG—
EV/EBITDA0.15
EV/Revenue—
P/S—
P/B0.77
EPS (TTM)-1.46
EPS (Forward)-1.29
52W Range
1.0107% of range7.800
52W High7.800 USD
52W Low1.010 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-60.81%
ROA-51.55%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-81.64M USD
CapEx (TTM)264.00K USD
FCF Margin—
FCF Yield-48.59%
Net Debt-115.74M USD
Net Debt/EBITDA1.45
Balance Sheet
Debt/Equity0.12
Current Ratio14.98
Quick Ratio14.76
Book Value/Sh1.937 USD
Cash/Share1.913 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.4 (Strong Buy)
Target (Mean)10.14 USD
Target Range3.000 USD – 20.00 USD
# Analysts7
Ownership
Shares Out.69.17M
Float37.03M
Insiders0.23%
Institutions90.16%
Short Interest
Short Ratio3.3d
Short % Float7.07%
Short % Out.5.01%
Shares Short3.46M
Short (prev mo.)3.57M
Technical
SMA 502.207 (-33.6%)
SMA 2004.034 (-63.7%)
Beta—
S&P 52W Chg27.70%
Avg Vol (30d)809.84K
Avg Vol (10d)742.66K
Technical Indicators
RSI (14)36.3
MACD-0.1926
MACD Signal-0.2417
MACD Hist.+0.0491
BB Upper1.944 USD
BB Middle1.630 USD
BB Lower1.316 USD
BB Width38.52%
ATR (14)0.1478 USD
Vol Ratio (20d)0.46x